waveform analysis system Search Results


90
AtCor Medical systems for pulse waveform analysis
Systems For Pulse Waveform Analysis, supplied by AtCor Medical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/systems for pulse waveform analysis/product/AtCor Medical
Average 90 stars, based on 1 article reviews
systems for pulse waveform analysis - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
BIOPAC waveform data acquisition/analysis software acqknowledge
Waveform Data Acquisition/Analysis Software Acqknowledge, supplied by BIOPAC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/waveform data acquisition/analysis software acqknowledge/product/BIOPAC
Average 90 stars, based on 1 article reviews
waveform data acquisition/analysis software acqknowledge - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
LiDCO Group continuous arterial waveform analysis system pulseco
Continuous Arterial Waveform Analysis System Pulseco, supplied by LiDCO Group, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/continuous arterial waveform analysis system pulseco/product/LiDCO Group
Average 90 stars, based on 1 article reviews
continuous arterial waveform analysis system pulseco - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Hamamatsu fdss waveform analysis software for cardiomyocytes
Patch clamp analysis of <t>cardiomyocytes</t> from control- and LQT-iPSC lines. (a) Representative APs of 1 Hz paced a control-iPSC-CM and an LQT-iPSC-CM from II-2 in . Ten consecutive waves are shown. (b) MDP, APA, and APD 90 from cardiomyocytes derived from the six lines: 201B7 ( n = 6), 409B2 ( n = 5), 692D2 ( n = 6), LQT1A1 ( n = 5), LQT1B1 ( n = 5), and LQT1C1 ( n = 7). Data are represented as means ± SEM; ∗∗ p < 0.005. (c) Representative current traces from control- and LQT1-iPSC-CMs. Upper, the protocol in current clamp recording. Middle, representative traces before and after perfusion with 3R4S-chromanol 293B (30 μ mol/l). Lower, 3R4S-chromanol 293B-subtraction. (d) I-V plots of I Ks at the end of the depolarizing step. 692D2 (control) ( n = 3), LQT1B1 ( n = 3); ∗ p < 0.05.
Fdss Waveform Analysis Software For Cardiomyocytes, supplied by Hamamatsu, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fdss waveform analysis software for cardiomyocytes/product/Hamamatsu
Average 90 stars, based on 1 article reviews
fdss waveform analysis software for cardiomyocytes - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Hamamatsu waveform analysis software
Patch clamp analysis of <t>cardiomyocytes</t> from control- and LQT-iPSC lines. (a) Representative APs of 1 Hz paced a control-iPSC-CM and an LQT-iPSC-CM from II-2 in . Ten consecutive waves are shown. (b) MDP, APA, and APD 90 from cardiomyocytes derived from the six lines: 201B7 ( n = 6), 409B2 ( n = 5), 692D2 ( n = 6), LQT1A1 ( n = 5), LQT1B1 ( n = 5), and LQT1C1 ( n = 7). Data are represented as means ± SEM; ∗∗ p < 0.005. (c) Representative current traces from control- and LQT1-iPSC-CMs. Upper, the protocol in current clamp recording. Middle, representative traces before and after perfusion with 3R4S-chromanol 293B (30 μ mol/l). Lower, 3R4S-chromanol 293B-subtraction. (d) I-V plots of I Ks at the end of the depolarizing step. 692D2 (control) ( n = 3), LQT1B1 ( n = 3); ∗ p < 0.05.
Waveform Analysis Software, supplied by Hamamatsu, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/waveform analysis software/product/Hamamatsu
Average 90 stars, based on 1 article reviews
waveform analysis software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Technika Inc aptt waveform analysis mda series
Clinical course of our patient. This graph shows FVIII (%), <t>aPTT</t> (s), and FVIII Ab (BU, Bethesda unit) levels. Abbreviations: rFVIIa, recombinant activated factor VII; Pd, prednisolone; Aza, azathioprine; HD, hospital day.
Aptt Waveform Analysis Mda Series, supplied by Technika Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/aptt waveform analysis mda series/product/Technika Inc
Average 90 stars, based on 1 article reviews
aptt waveform analysis mda series - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
DATAQ Instruments waveform analysis software windq 2000
Clinical course of our patient. This graph shows FVIII (%), <t>aPTT</t> (s), and FVIII Ab (BU, Bethesda unit) levels. Abbreviations: rFVIIa, recombinant activated factor VII; Pd, prednisolone; Aza, azathioprine; HD, hospital day.
Waveform Analysis Software Windq 2000, supplied by DATAQ Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/waveform analysis software windq 2000/product/DATAQ Instruments
Average 90 stars, based on 1 article reviews
waveform analysis software windq 2000 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Hamamatsu waveform analysis of cardiomyocyte software
Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC <t>2v-cardiomyocyte</t> in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.
Waveform Analysis Of Cardiomyocyte Software, supplied by Hamamatsu, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/waveform analysis of cardiomyocyte software/product/Hamamatsu
Average 90 stars, based on 1 article reviews
waveform analysis of cardiomyocyte software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
AtCor Medical customized waveform analysis software sphygmocor version 7.1
Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC <t>2v-cardiomyocyte</t> in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.
Customized Waveform Analysis Software Sphygmocor Version 7.1, supplied by AtCor Medical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/customized waveform analysis software sphygmocor version 7.1/product/AtCor Medical
Average 90 stars, based on 1 article reviews
customized waveform analysis software sphygmocor version 7.1 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Tektronix inc waveform analysis package tams (tektronix inc)
Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC <t>2v-cardiomyocyte</t> in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.
Waveform Analysis Package Tams (Tektronix Inc), supplied by Tektronix inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/waveform analysis package tams (tektronix inc)/product/Tektronix inc
Average 90 stars, based on 1 article reviews
waveform analysis package tams (tektronix inc) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Institute for Clinical Pharmacodynamics waveform analysis
Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC <t>2v-cardiomyocyte</t> in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.
Waveform Analysis, supplied by Institute for Clinical Pharmacodynamics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/waveform analysis/product/Institute for Clinical Pharmacodynamics
Average 90 stars, based on 1 article reviews
waveform analysis - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Weisang GmbH waveform analysis software (flex pro7.0
Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC <t>2v-cardiomyocyte</t> in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.
Waveform Analysis Software (Flex Pro7.0, supplied by Weisang GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/waveform analysis software (flex pro7.0/product/Weisang GmbH
Average 90 stars, based on 1 article reviews
waveform analysis software (flex pro7.0 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Patch clamp analysis of cardiomyocytes from control- and LQT-iPSC lines. (a) Representative APs of 1 Hz paced a control-iPSC-CM and an LQT-iPSC-CM from II-2 in . Ten consecutive waves are shown. (b) MDP, APA, and APD 90 from cardiomyocytes derived from the six lines: 201B7 ( n = 6), 409B2 ( n = 5), 692D2 ( n = 6), LQT1A1 ( n = 5), LQT1B1 ( n = 5), and LQT1C1 ( n = 7). Data are represented as means ± SEM; ∗∗ p < 0.005. (c) Representative current traces from control- and LQT1-iPSC-CMs. Upper, the protocol in current clamp recording. Middle, representative traces before and after perfusion with 3R4S-chromanol 293B (30 μ mol/l). Lower, 3R4S-chromanol 293B-subtraction. (d) I-V plots of I Ks at the end of the depolarizing step. 692D2 (control) ( n = 3), LQT1B1 ( n = 3); ∗ p < 0.05.

Journal: Stem Cells International

Article Title: Optical Recording of Action Potentials in Human Induced Pluripotent Stem Cell-Derived Cardiac Single Cells and Monolayers Generated from Long QT Syndrome Type 1 Patients

doi: 10.1155/2019/7532657

Figure Lengend Snippet: Patch clamp analysis of cardiomyocytes from control- and LQT-iPSC lines. (a) Representative APs of 1 Hz paced a control-iPSC-CM and an LQT-iPSC-CM from II-2 in . Ten consecutive waves are shown. (b) MDP, APA, and APD 90 from cardiomyocytes derived from the six lines: 201B7 ( n = 6), 409B2 ( n = 5), 692D2 ( n = 6), LQT1A1 ( n = 5), LQT1B1 ( n = 5), and LQT1C1 ( n = 7). Data are represented as means ± SEM; ∗∗ p < 0.005. (c) Representative current traces from control- and LQT1-iPSC-CMs. Upper, the protocol in current clamp recording. Middle, representative traces before and after perfusion with 3R4S-chromanol 293B (30 μ mol/l). Lower, 3R4S-chromanol 293B-subtraction. (d) I-V plots of I Ks at the end of the depolarizing step. 692D2 (control) ( n = 3), LQT1B1 ( n = 3); ∗ p < 0.05.

Article Snippet: Binning was set to 4 × 4, and the measurement interval was every 4 ms. Cardiomyocyte monolayers 7–10 days after seeding on each well were stimulated at 1 Hz with 1 ms depolarizing pulses at 10 V. Analysis of APD 90 was performed with FDSS Waveform Analysis software for cardiomyocytes (U8524-12; Hamamatsu Photonics).

Techniques: Patch Clamp, Control, Derivative Assay

AP measurements of single cells using a membrane potential dye. (a) Examples of AP waves from control (409B2) measured by the dye. ROIs (1)–(5) are ventricular type. ROI (5) (green wave) shows long APD. (b) Examples of AP waves from LQT1B1. ROIs (1)–(4) are ventricular type with long APD. ROI (4) (purple wave) shows EADs. ROI (5) (green wave) is nodal type. (c) Proportion of subtypes in 3 control- and 3 LQT1-iPSC-CMs: 201B7 ( n = 128), 409B2 ( n = 41), 692D2 ( n = 92), LQT1A1 ( n = 192), LQT1B1 ( n = 101), and LQT1C1 ( n = 202). Ventricular-type cells predominate in all six lines. (d) Representative EADs in a ventricular-type cell from LQT1B1. The EADs were defined as over 20% of the AP amplitude. Arrows show EADs. (e) Occurrence ratio of EADs in ventricular cardiomyocytes from the six lines. The number of ventricular cells was used as the denominator; ∗ p < 0.05.

Journal: Stem Cells International

Article Title: Optical Recording of Action Potentials in Human Induced Pluripotent Stem Cell-Derived Cardiac Single Cells and Monolayers Generated from Long QT Syndrome Type 1 Patients

doi: 10.1155/2019/7532657

Figure Lengend Snippet: AP measurements of single cells using a membrane potential dye. (a) Examples of AP waves from control (409B2) measured by the dye. ROIs (1)–(5) are ventricular type. ROI (5) (green wave) shows long APD. (b) Examples of AP waves from LQT1B1. ROIs (1)–(4) are ventricular type with long APD. ROI (4) (purple wave) shows EADs. ROI (5) (green wave) is nodal type. (c) Proportion of subtypes in 3 control- and 3 LQT1-iPSC-CMs: 201B7 ( n = 128), 409B2 ( n = 41), 692D2 ( n = 92), LQT1A1 ( n = 192), LQT1B1 ( n = 101), and LQT1C1 ( n = 202). Ventricular-type cells predominate in all six lines. (d) Representative EADs in a ventricular-type cell from LQT1B1. The EADs were defined as over 20% of the AP amplitude. Arrows show EADs. (e) Occurrence ratio of EADs in ventricular cardiomyocytes from the six lines. The number of ventricular cells was used as the denominator; ∗ p < 0.05.

Article Snippet: Binning was set to 4 × 4, and the measurement interval was every 4 ms. Cardiomyocyte monolayers 7–10 days after seeding on each well were stimulated at 1 Hz with 1 ms depolarizing pulses at 10 V. Analysis of APD 90 was performed with FDSS Waveform Analysis software for cardiomyocytes (U8524-12; Hamamatsu Photonics).

Techniques: Membrane, Control

AP measurements in a cardiomyocyte monolayer. Data are represented as means ± SEM. (a) An example phase contrast image of the monolayer culture. Scale bar, 500 μ m. (b) Representative AP of a paced control-iPSC-CM monolayer. APD 90 was calculated from the average of 10 consecutive waves. (c) APD 90 from 3 control- and 3 LQT-iPSC-CM monolayers: 201B7 ( n = 3), 409B2 ( n = 3), 692D2 ( n = 3), LQT1A1 ( n = 3), LQT1B1 ( n = 3), and LQT1C1 ( n = 3). LQT-iPSC-CMs showed longer APD than controls; ∗∗ p < 0.005.

Journal: Stem Cells International

Article Title: Optical Recording of Action Potentials in Human Induced Pluripotent Stem Cell-Derived Cardiac Single Cells and Monolayers Generated from Long QT Syndrome Type 1 Patients

doi: 10.1155/2019/7532657

Figure Lengend Snippet: AP measurements in a cardiomyocyte monolayer. Data are represented as means ± SEM. (a) An example phase contrast image of the monolayer culture. Scale bar, 500 μ m. (b) Representative AP of a paced control-iPSC-CM monolayer. APD 90 was calculated from the average of 10 consecutive waves. (c) APD 90 from 3 control- and 3 LQT-iPSC-CM monolayers: 201B7 ( n = 3), 409B2 ( n = 3), 692D2 ( n = 3), LQT1A1 ( n = 3), LQT1B1 ( n = 3), and LQT1C1 ( n = 3). LQT-iPSC-CMs showed longer APD than controls; ∗∗ p < 0.005.

Article Snippet: Binning was set to 4 × 4, and the measurement interval was every 4 ms. Cardiomyocyte monolayers 7–10 days after seeding on each well were stimulated at 1 Hz with 1 ms depolarizing pulses at 10 V. Analysis of APD 90 was performed with FDSS Waveform Analysis software for cardiomyocytes (U8524-12; Hamamatsu Photonics).

Techniques: Control

AP measurements in cardiomyocyte monolayers using a high-throughput plate reader. (a) Representative AP waves on a 96-well plate. Pacing at 1 Hz starts 10 s after recording. (b) Cisapride prolonged APD 90 of both control- and LQT1-iPSC-CMs; 692D2 (control) ( n = 3), LQT1B1 ( n = 5). (c) Cisapride prolonged APD 90 of both control- and LQT1-iPSC-CMs with 100 nM isoproterenol; 692D2 ( n = 5), LQT1B1 ( n = 3). (d) Erythromycin prolonged APD 90 of both control- and LQT1-iPSC-CMs with 100 nM isoproterenol; 692D2 ( n = 4), LQT1B1 ( n = 3). LQT-iPSC-CM monolayers in 300 nM and 1000 nM cisapride were not synchronized at 1 Hz pacing. Data are represented as means ± SEM; ∗∗ p < 0.005, ∗ p < 0.05.

Journal: Stem Cells International

Article Title: Optical Recording of Action Potentials in Human Induced Pluripotent Stem Cell-Derived Cardiac Single Cells and Monolayers Generated from Long QT Syndrome Type 1 Patients

doi: 10.1155/2019/7532657

Figure Lengend Snippet: AP measurements in cardiomyocyte monolayers using a high-throughput plate reader. (a) Representative AP waves on a 96-well plate. Pacing at 1 Hz starts 10 s after recording. (b) Cisapride prolonged APD 90 of both control- and LQT1-iPSC-CMs; 692D2 (control) ( n = 3), LQT1B1 ( n = 5). (c) Cisapride prolonged APD 90 of both control- and LQT1-iPSC-CMs with 100 nM isoproterenol; 692D2 ( n = 5), LQT1B1 ( n = 3). (d) Erythromycin prolonged APD 90 of both control- and LQT1-iPSC-CMs with 100 nM isoproterenol; 692D2 ( n = 4), LQT1B1 ( n = 3). LQT-iPSC-CM monolayers in 300 nM and 1000 nM cisapride were not synchronized at 1 Hz pacing. Data are represented as means ± SEM; ∗∗ p < 0.005, ∗ p < 0.05.

Article Snippet: Binning was set to 4 × 4, and the measurement interval was every 4 ms. Cardiomyocyte monolayers 7–10 days after seeding on each well were stimulated at 1 Hz with 1 ms depolarizing pulses at 10 V. Analysis of APD 90 was performed with FDSS Waveform Analysis software for cardiomyocytes (U8524-12; Hamamatsu Photonics).

Techniques: High Throughput Screening Assay, Control

Clinical course of our patient. This graph shows FVIII (%), aPTT (s), and FVIII Ab (BU, Bethesda unit) levels. Abbreviations: rFVIIa, recombinant activated factor VII; Pd, prednisolone; Aza, azathioprine; HD, hospital day.

Journal: Blood research

Article Title: Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A

doi: 10.5045/br.2013.48.1.58

Figure Lengend Snippet: Clinical course of our patient. This graph shows FVIII (%), aPTT (s), and FVIII Ab (BU, Bethesda unit) levels. Abbreviations: rFVIIa, recombinant activated factor VII; Pd, prednisolone; Aza, azathioprine; HD, hospital day.

Article Snippet: APTT waveform analysis (MDA series; Organon, Technika) of the patient's plasma showed a delayed clotting pattern compared to normal pooled plasma ( ).

Techniques: Recombinant

The APTT waveform analysis of the patient's plasma. Minor hemostatic effect by infusion. Abbreviations: Patient Pre, Pre-treatment; Patient Post, Post-treatment; NP, normal pooled plasma; Coag, coagulation.

Journal: Blood research

Article Title: Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A

doi: 10.5045/br.2013.48.1.58

Figure Lengend Snippet: The APTT waveform analysis of the patient's plasma. Minor hemostatic effect by infusion. Abbreviations: Patient Pre, Pre-treatment; Patient Post, Post-treatment; NP, normal pooled plasma; Coag, coagulation.

Article Snippet: APTT waveform analysis (MDA series; Organon, Technika) of the patient's plasma showed a delayed clotting pattern compared to normal pooled plasma ( ).

Techniques: Clinical Proteomics, Coagulation

Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.

Journal: Frontiers in Pharmacology

Article Title: High-Throughput Drug Screening System Based on Human Induced Pluripotent Stem Cell-Derived Atrial Myocytes ∼ A Novel Platform to Detect Cardiac Toxicity for Atrial Arrhythmias

doi: 10.3389/fphar.2021.680618

Figure Lengend Snippet: Cardiac differentiation from hiPSCs (A) Schematic of the protocol for the differentiation of cardiomyocytes from hiPS cells with (RA (+)) or without RA (RA (−)) treatment (B) The ratio of cardiomyocytes quantified by immunostaining with cardiac troponin-T (cTnT). The proportion of cTnT positive cells was 93.91 ± 2.51% in CT (control hiPS-CMs), or 96.79 ± 1.81% in AM (RA-treated hiPS-CMs), respectively (P = N.S.). Error bars represent SD of the mean from the values of independent experiments. n = 3. N.S., not significant (C) Immunofluorescence analysis of the percentage of MLC2a (atrial isoform) and MLC2v (ventricular isoform) positive expression in the CT and AM. Error bars represent SD of the mean from the values of independent experiments. ** p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in CT, ## p < 0.01 for comparison with MLC 2a+/MLC 2v-cardiomyocyte in AM, n = 3.

Article Snippet: Recording data were analyzed using Waveform Analysis of Cardiomyocyte Software (Ver.1.2.1J, Hamamatsu Photonics K.K.).

Techniques: Immunostaining, Control, Immunofluorescence, Expressing, Comparison